Buchanan et al., 2019 - Google Patents
An improved clinical model to predict stimulated C‐peptide in children with recent‐onset type 1 diabetesBuchanan et al., 2019
View PDF- Document ID
- 13409326463310403451
- Author
- Buchanan K
- Mehdi A
- Hughes I
- Cotterill A
- Le Cao K
- Thomas R
- Harris M
- Publication year
- Publication venue
- Pediatric diabetes
External Links
Snippet
Background Stimulated C‐peptide measurement after a mixed meal tolerance test (MMTT) is the accepted gold standard for assessing residual beta‐cell function in type 1 diabetes (T1D); however, this approach is impractical outside of clinical trials. Objective To develop …
- 108010075254 C-Peptide 0 title abstract description 100
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/573—Immunoassay; Biospecific binding assay for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Barker et al. | Age‐dependent decline of β‐cell function in type 1 diabetes after diagnosis: a multi‐centre longitudinal study | |
Steck et al. | Residual beta‐cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls | |
Nagl et al. | Factors contributing to partial remission in type 1 diabetes: analysis based on the insulin dose‐adjusted HbA1c in 3657 children and adolescents from Germany and Austria | |
Singh et al. | Surrogate markers of insulin resistance: A review | |
Chung et al. | Inflammation‐associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms | |
Retnakaran et al. | Evaluation of proposed oral disposition index measures in relation to the actual disposition index | |
Dabelea et al. | Development, validation and use of an insulin sensitivity score in youths with diabetes: the SEARCH for Diabetes in Youth study | |
Fröhlich‐Reiterer et al. | Screening frequency for celiac disease and autoimmune thyroiditis in children and adolescents with type 1 diabetes mellitus–data from a German/Austrian multicentre survey | |
den Uyl et al. | Metabolic effects of high‐dose prednisolone treatment in early rheumatoid arthritis: Balance between diabetogenic effects and inflammation reduction | |
Hanley et al. | Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study | |
Buchanan et al. | An improved clinical model to predict stimulated C‐peptide in children with recent‐onset type 1 diabetes | |
Max Andersen et al. | Partial remission definition: validation based on the insulin dose‐adjusted HbA1c (IDAA1C) in 129 Danish children with new‐onset type 1 diabetes | |
Jennersjö et al. | Pedometer‐determined physical activity is linked to low systemic inflammation and low arterial stiffness in type 2 diabetes | |
Wiklund et al. | Normal‐weight obesity and cardiometabolic risk: A 7‐year longitudinal study in girls from prepuberty to early adulthood | |
Hope et al. | Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia | |
Al‐Zubeidi et al. | Low vitamin D level in pediatric patients with new onset type 1 diabetes is common, especially if in ketoacidosis | |
Myhill et al. | Chronic complications and mortality in community‐based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study | |
Margolis‐Gil et al. | Which predictors differentiate between obese children and adolescents with cardiometabolic complications and those with metabolically healthy obesity? | |
Sosenko et al. | The influence of body mass index and age on C‐peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial‐type 1 | |
Feng et al. | Low birth weight, cumulative obesity dose, and the risk of incident type 2 diabetes | |
Hwang et al. | Increased apoB/A‐I ratio independently associated with Type 2 diabetes mellitus: cross‐sectional study in a Korean population | |
Chadha et al. | Reproducibility of a prediabetes classification in a contemporary population | |
Chepulis et al. | Glycaemic control across the lifespan in a cohort of New Zealand patients with type 1 diabetes mellitus | |
Ruan et al. | Mixed‐meal tolerance test to assess residual beta‐cell secretion: Beyond the area‐under‐curve of plasma C‐peptide concentration | |
Simmons et al. | Sex‐and age‐dependent effects of celiac disease on growth and weight gain in children with type 1 diabetes: Analysis of the type 1 diabetes Exchange Clinic Registry |